804 related articles for article (PubMed ID: 33685605)
41. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Cakmak ME; Yeğit OO; Öztop N
Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
[TBL] [Abstract][Full Text] [Related]
42. EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.
Agache I; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong PY; O'Mahony L; Schwarze J; Warner A; Werfel T; Palomares O; Jutel M
Allergy; 2022 Jan; 77(1):17-38. PubMed ID: 34324716
[TBL] [Abstract][Full Text] [Related]
43. Justification for IgE as a therapeutic target in chronic spontaneous urticaria.
Sánchez-Borges M; Capriles-Hulet A; Caballero-Fonseca F; González-Aveledo L
Eur Ann Allergy Clin Immunol; 2017 Jul; 49(4):148-153. PubMed ID: 28752717
[TBL] [Abstract][Full Text] [Related]
44. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
Maurer M; Zuberbier T; Metz M
Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
[TBL] [Abstract][Full Text] [Related]
45. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
46. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
[TBL] [Abstract][Full Text] [Related]
47. Urticaria and Angioedema: an Update on Classification and Pathogenesis.
Radonjic-Hoesli S; Hofmeier KS; Micaletto S; Schmid-Grendelmeier P; Bircher A; Simon D
Clin Rev Allergy Immunol; 2018 Feb; 54(1):88-101. PubMed ID: 28748365
[TBL] [Abstract][Full Text] [Related]
48. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
[TBL] [Abstract][Full Text] [Related]
49. Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.
Özçeker D; Can PK; Terzi Ö; Ornek SA; Değirmentepe EN; Kızıltac K; Sarac E; Kocatürk E
Pediatr Allergy Immunol; 2023 Feb; 34(2):e13925. PubMed ID: 36825740
[TBL] [Abstract][Full Text] [Related]
50. A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.
Folci M; Ramponi G; Brunetta E
Adv Exp Med Biol; 2021; 1326():111-137. PubMed ID: 33385176
[TBL] [Abstract][Full Text] [Related]
51. Pediatric chronic spontaneous urticaria: a brief clinician's guide.
Votto M; Achilli G; De Filippo M; Licari A; Marseglia A; Moiraghi A; Di Sabatino A; Marseglia GL
Expert Rev Clin Immunol; 2022 Sep; 18(9):889-899. PubMed ID: 35833360
[TBL] [Abstract][Full Text] [Related]
52. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE.
Buttgereit T; Vera C; Aulenbacher F; Church MK; Hawro T; Asero R; Bauer A; Bizjak M; Bouillet L; Dissemond J; Fomina D; Giménez-Arnau AM; Grattan C; Gregoriou S; Kulthanan K; Kasperska-Zajac A; Kocatürk E; Makris M; Kolkhir P; Weller K; Magerl M; Maurer M
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3515-3525.e4. PubMed ID: 37604426
[TBL] [Abstract][Full Text] [Related]
53. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
Gimenez-Arnau AM; Salman A; Podder I
Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
[TBL] [Abstract][Full Text] [Related]
54. Omalizumab response correlates with reduced IFN-γ-, IL-10- and IL-31-secreting cells in chronic spontaneous urticaria.
Rauber MM; Pickert J; Holiangu L; Möbs C; Pfützner W
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2078-2085. PubMed ID: 31954076
[TBL] [Abstract][Full Text] [Related]
55. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
Kocatürk E; Başkan EB; Küçük ÖS; Özdemir M; Örnek S; Can PK; Haşal E; Engin B; Atakan N; Alpsoy E
An Bras Dermatol; 2022; 97(5):592-600. PubMed ID: 35853771
[TBL] [Abstract][Full Text] [Related]
56. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
57. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
58. D-dimer levels decline after immunosuppressive treatment rather than anticoagulant treatment in severe autoimmune chronic spontaneous urticaria.
Baskurt D; Sarac E; Asero R; Kocatürk E
Eur Ann Allergy Clin Immunol; 2024 Jan; 56(1):42-44. PubMed ID: 36305339
[TBL] [Abstract][Full Text] [Related]
59. Omalizumab treatment in combination with any other biologics: Is it really a safe duo?
Koç Yıldırım S; Erbağcı E; Hapa A
Australas J Dermatol; 2023 May; 64(2):229-233. PubMed ID: 36866918
[TBL] [Abstract][Full Text] [Related]
60. Omalizumab in severe chronic urticaria: are slow and non-responders different?
Asero R
Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
